LivaNova (LIVN) to Release Quarterly Earnings on Wednesday

LivaNova (NASDAQ:LIVN - Get Free Report) is projected to issue its Q1 2025 quarterly earnings data before the market opens on Wednesday, May 7th. Analysts expect LivaNova to post earnings of $0.75 per share and revenue of $302.34 million for the quarter.

LivaNova Price Performance

LIVN stock traded down $0.01 during trading on Friday, hitting $36.78. The stock had a trading volume of 925,924 shares, compared to its average volume of 610,858. LivaNova has a 1-year low of $32.48 and a 1-year high of $64.48. The stock has a market cap of $2.01 billion, a price-to-earnings ratio of 87.57 and a beta of 0.84. The company's 50 day moving average price is $37.98 and its two-hundred day moving average price is $45.58. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37.

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. Stifel Nicolaus lowered their target price on shares of LivaNova from $72.00 to $60.00 and set a "buy" rating for the company in a research note on Wednesday, February 26th. Barclays reduced their target price on LivaNova from $58.00 to $56.00 and set an "equal weight" rating on the stock in a research report on Friday, March 7th. Needham & Company LLC restated a "buy" rating and issued a $64.00 price target on shares of LivaNova in a report on Monday, March 17th. Wolfe Research lowered shares of LivaNova from an "outperform" rating to a "peer perform" rating in a report on Wednesday, February 26th. Finally, The Goldman Sachs Group decreased their target price on shares of LivaNova from $64.00 to $55.00 and set a "buy" rating on the stock in a research report on Monday, March 3rd. Two research analysts have rated the stock with a hold rating, five have assigned a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $61.17.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.